Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Demirkol, DemetYildizdas, DincerBAYRAKCİ, BENANKARAPINAR, BÜLENTKendirli, TanilKÖROĞLU, TOLGA FİKRİDURSUN, OĞUZErkek, NilgunGedik, HakanCitak, AgopKESİCİ, SELMANKarabocuoglu, MetinCarcillo, Joseph A.2020-10-222020-10-222012-01-01Demirkol D., Yildizdas D., BAYRAKCİ B., KARAPINAR B., Kendirli T., KÖROĞLU T. F. , DURSUN O., Erkek N., Gedik H., Citak A., et al., -Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?-, CRITICAL CARE, cilt.16, 2012http://hdl.handle.net/20.500.12645/24689Introduction: Hyperferritinemia is associated with increased mortality in pediatric sepsis, multiple organ dysfunction syndrome (MODS), and critical illness. The International Histiocyte Society has recommended that children with hyperferritinemia and secondary hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) should be treated with the same immunosuppressant/cytotoxic therapies used to treat primary HLH. We hypothesized that patients with hyperferritinemia associated secondary HLH/sepsis/MODS/MAS can be successfully treated with a less immunosuppressant approach than is recommended for primary HLH.info:eu-repo/semantics/openAccessHyperferritinemiaHyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?ArticleWOS:0003131968000188486026191310.1186/cc1125622715953